Ultragenyx Pharmaceutical (RARE) Other Non-Current Assets (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Other Non-Current Assets of $61.0 million for Q1 2026, down 2.2% year-over-year from $62.4 million in Q1 2025, and up 1.67% quarter-over-quarter from $60.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Other Non-Current Assets for 14 consecutive years, with $61.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 2.2% year-over-year to $61.0 million; the TTM figure through Mar 2026 stood at $61.0 million (down 2.2% YoY), while the FY2025 annual figure was $60.0 million, down 4.76% from the prior year.
- Other Non-Current Assets climbed to $61.0 million in Q1 2026 per RARE's latest filing, from $60.0 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $63.0 million in Q4 2024 and bottomed at $18.3 million in Q3 2022.
- Historically, Other Non-Current Assets has averaged $45.6 million across 5 years, with a median of $53.9 million in 2024.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets jumped 169.42% — and 2025, when it declined 4.76%.
- Ultragenyx Pharmaceutical's Other Non-Current Assets stood at $48.3 million in 2022, then increased by 19.34% to $57.7 million in 2023, then advanced by 9.21% to $63.0 million in 2024, then slipped by 4.76% to $60.0 million in 2025, then advanced by 1.67% to $61.0 million in 2026.
- Business Quant data shows RARE's Other Non-Current Assets at $61.0 million in Q1 2026, $60.0 million in Q4 2025, and $57.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 63.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.00 Mn |
| Mar 31, 2026 | 61.00 Mn |
| Dec 31, 2025 | 60.00 Mn |
| Sep 30, 2025 | 57.86 Mn |
| Jun 30, 2025 | 60.12 Mn |
| Mar 31, 2025 | 62.37 Mn |
| Dec 31, 2024 | 63.00 Mn |
| Sep 30, 2024 | 53.87 Mn |
| Jun 30, 2024 | 53.77 Mn |
| Mar 31, 2024 | 59.97 Mn |
| Dec 31, 2023 | 57.69 Mn |
| Sep 30, 2023 | 27.90 Mn |
| Jun 30, 2023 | 26.49 Mn |
| Mar 31, 2023 | 22.26 Mn |
| Dec 31, 2022 | 48.34 Mn |
| Sep 30, 2022 | 18.29 Mn |
| Jun 30, 2022 | 21.14 Mn |
| Mar 31, 2022 | 21.22 Mn |
| Dec 31, 2021 | 20.56 Mn |
| Sep 30, 2021 | 16.42 Mn |